Glycomet SR is a next-generation, sustained-release formulation of metformin hydrochloride, specifically engineered to enhance patient adherence and glycemic management in type 2 diabetes mellitus. By utilizing a sophisticated drug delivery system, it ensures a gradual and consistent release of metformin, minimizing peak-trough fluctuations and reducing the incidence of gastrointestinal side effects commonly associated with immediate-release formulations. This medication works primarily by decreasing hepatic glucose production and improving insulin sensitivity in peripheral tissues, making it a cornerstone therapy in diabetes care. It is indicated as monotherapy or in combination with other antidiabetic agents, under appropriate medical supervision, to achieve and maintain target blood glucose levels.

Features

• Contains metformin hydrochloride in sustained-release tablets (e.g., 500 mg, 1000 mg)
• Utilizes a hydrophilic matrix system for controlled, prolonged drug release over 24 hours
• Designed for once-daily dosing to support treatment adherence
• Bioequivalent to immediate-release metformin in terms of overall exposure (AUC)
• Available in various strengths to allow for individualized titration
• Film-coated for ease of swallowing and reduced potential for esophageal irritation

Benefits

• Provides steady, around-the-clock glycemic control with reduced plasma concentration peaks
• Lowers the risk of gastrointestinal adverse events compared to immediate-release metformin
• Enhances patient compliance through simplified once-daily dosing
• Effectively reduces HbA1c levels and fasting plasma glucose
• May contribute to modest weight loss or weight neutrality in many patients
• Offers a well-established safety profile with decades of clinical use and evidence

Common use

Glycomet SR is primarily prescribed for the management of type 2 diabetes mellitus in adults. It is used as an initial pharmacological intervention—especially in overweight or obese patients—or as an add-on therapy when lifestyle modifications and other antidiabetic agents do not suffice. It may also be used off-label in certain cases of polycystic ovary syndrome (PCOS) under specialist guidance, owing to its insulin-sensitizing effects.

Dosage and direction

The initial recommended dose is typically 500 mg once daily, taken with the evening meal. Dosage may be gradually increased, at intervals of not less than one week, based on therapeutic response and tolerability, up to a maximum of 2000 mg once daily. Tablets must be swallowed whole and must not be crushed, chewed, or split. Consistent timing of administration is advised to maintain stable drug levels.

Precautions

• Renal function should be assessed before initiation and periodically thereafter; use is not recommended if eGFR is below 30 mL/min/1.73m².
• Avoid use in conditions predisposing to renal impairment, dehydration, or hypoxia.
• Temporary discontinuation may be required prior to iodinated contrast imaging procedures.
• Monitor vitamin B12 levels annually during long-term therapy due to risk of deficiency.
• Use with caution in elderly patients and those with hepatic impairment.
• Inform healthcare provider of any upcoming surgical procedures.

Contraindications

• Hypersensitivity to metformin or any excipients in the formulation.
• Severe renal impairment (eGFR <30 mL/min/1.73m²) or renal disease.
• Acute or chronic metabolic acidosis, including diabetic ketoacidosis.
• Acute conditions with potential to alter renal function: dehydration, severe infection, shock.
• History of lactic acidosis.

Possible side effects

Common side effects (often dose-related and transient) may include:

• Nausea, vomiting, diarrhea, abdominal discomfort
• Metallic taste, decreased appetite

Less common but serious adverse effects:

• Lactic acidosis (symptoms include malaise, myalgia, respiratory distress, abdominal pain)
• Vitamin B12 deficiency with prolonged use
• Hypoglycemia (especially when used with other glucose-lowering agents)

Drug interaction

• Cationic drugs (e.g., amiloride, digoxin, morphine, procainamide, quinidine, quinine, ranitidine, triamterene, trimethoprim, vancomycin) may compete for renal tubular secretion and increase metformin levels.
• Alcohol: increases risk of lactic acidosis; avoid excessive consumption.
• Glucocorticoids, diuretics, sympathomimetics may reduce hypoglycemic effect.
• Hypoglycemic risk increased with sulfonylureas, insulin, meglitinides.

Missed dose

If a dose is missed, it should be taken as soon as remembered on the same day. If it is near the time of the next dose, skip the missed dose and resume the regular schedule. Do not double the dose.

Overdose

Overdose may lead to lactic acidosis, a medical emergency characterized by acid-base imbalance, electrolyte disturbances, and hypoglycemia. Symptoms include vomiting, abdominal pain, hypothermia, hypotension, and tachycardia. Hospitalization is required; hemodialysis may be effective in removing accumulated metformin.

Storage

Store below 30°C, in a dry place, protected from light and moisture. Keep out of reach of children. Do not use after the expiration date printed on the packaging.

Disclaimer

This information is intended for educational purposes and does not replace professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting or altering any medication regimen. Individual patient needs and responses may vary.

Reviews

“Glycomet SR has significantly improved my glycemic control with minimal side effects. The once-daily dose is convenient and easy to remember.” – Patient, 54
“As an endocrinologist, I find Glycomet SR offers a balanced efficacy-tolerability profile, especially beneficial for patients struggling with GI issues on immediate-release metformin.” – Dr. A. Sharma, MD
“Switching to the sustained-release version reduced my HbA1c by 1.2% within three months without the abdominal discomfort I previously experienced.” – Patient, 61